News
MYCOF
0.0076
0.00%
0.0000
Weekly Report: what happened at MYCOF last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at MYCOF last week (0708-0712)?
Weekly Report · 07/15 09:53
Weekly Report: what happened at MYCOF last week (0701-0705)?
Weekly Report · 07/08 09:54
Weekly Report: what happened at MYCOF last week (0624-0628)?
Weekly Report · 07/01 09:54
Weekly Report: what happened at MYCOF last week (0617-0621)?
Weekly Report · 06/24 09:57
Weekly Report: what happened at MYCOF last week (0610-0614)?
Weekly Report · 06/17 09:54
Weekly Report: what happened at MYCOF last week (0603-0607)?
Weekly Report · 06/10 09:55
Psychedelic stocks fall as FDA panel rejects MDMA therapy
Psychedelic stocks fall as FDA panel rejects MDMA therapy. The selloff comes after a panel of independent advisors to the U.S. FDA declined to endorse marketing authorization for psychiatric therapy. Notable decliners include Mind Medicine, Atai Life Sciences and Cybin.
Seeking Alpha · 06/05 11:17
Weekly Report: what happened at MYCOF last week (0527-0531)?
Weekly Report · 06/03 09:56
Psychedelic stocks mixed as FDA comments on MDMA therapy
Healthcare Psychedelic stocks mixed as FDA comments on MDMA therapy. If approved, MDMA is set to become the first psychedelic-assisted therapy authorized by the FDA. Leading psychedelic-focused drug developers include GH Research, Mind Medicine, and Cybin. FDA commented on Lykos Therapeutics' marketing application for midomafetamine (MDMA)
Seeking Alpha · 05/31 14:43
Weekly Report: what happened at MYCOF last week (0520-0524)?
Weekly Report · 05/27 09:58
Weekly Report: what happened at MYCOF last week (0513-0517)?
Weekly Report · 05/20 09:55
Weekly Report: what happened at MYCOF last week (0506-0510)?
Weekly Report · 05/13 09:59
Weekly Report: what happened at MYCOF last week (0429-0503)?
Weekly Report · 05/06 10:02
Mydecine receives management cease trade order
Mydecine receives management cease trade order May 03, 2024. Mydecine Innovations Group Inc. (MYCOF) Stock. The company expects annual audited financial statements to be finalized before June 28, 2024 or sooner. The British Columbia Securities Commission issued a temporary Management Cease Trade Order on April 26.
Seeking Alpha · 05/03 06:28
Weekly Report: what happened at MYCOF last week (0422-0426)?
Weekly Report · 04/29 10:04
Weekly Report: what happened at MYCOF last week (0415-0419)?
Weekly Report · 04/22 10:00
Weekly Report: what happened at MYCOF last week (0408-0412)?
Weekly Report · 04/15 09:56
Weekly Report: what happened at MYCOF last week (0401-0405)?
Weekly Report · 04/08 09:59
Weekly Report: what happened at MYCOF last week (0325-0329)?
Weekly Report · 04/01 09:58
More
Webull provides a variety of real-time MYCOF stock news. You can receive the latest news about Mydecine Innovations Group Inc through multiple platforms. This information may help you make smarter investment decisions.
About MYCOF
Mydecine Innovations Group Inc. is a Canada-based biopharmaceutical company. The Company’s principal activities are research, drug development and clinical trials of psilocybin products. The Company offers healthcare professionals a variety serotonin-modulating medications by developing drug families derived from Psilocybin and MDMA. The Company is developing several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. It is also developing MYCO-006, short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.